Thalidomide suppresses T- and B-cell responses to myelin antigen in experimental allergic neuritis

Clinical Neuropharmacology

Volumn 20, Issue 2, 1997, Pages 152-164

  Zhu, Jie ^a   Bai, Xuefeng ^a   Mix, Eilhard ^b   Van Der Meide, Peter H ^c   Zwingenberger, Kai ^d   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^d GRÜNENTHAL GMBH   (Germany)

Author keywords

Autoimmunity; Dexamethasone; Experimental allergic neuritis; Interferon ; Thalidomide

Indexed keywords

DEXAMETHASONE; MYELIN PROTEIN; PHYTOHEMAGGLUTININ; THALIDOMIDE;

ALLERGIC NEUROPATHY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; DIAGNOSIS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030960758     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199704000-00007     Document Type: Article

References (42)

1. Hartung HP. Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol 1995;8:191-9.
2. Koski CL, Gratz E, Sutherland J, Mayer RF. Clinical correlation with anti-peripheral nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol 1988;19:573-7.
3. Khalili-Shirazi A, Hughes RAC, Brostoff SW, Linington C, Gregson N. T cell responses to myelin in Guillain-Barré syndrome. J Neurol Sci 1992;111:200-3.
4. Hartung HP. Immune-mediated demyelination. Ann Neurol 1993;33:563-7.
5. Thornton CA, Griggs C. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994;35:749-52.
6. Jung S, Huitinga I, Schmidt B, et al. Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci 1993;119:195-202.
7. Zhu J, Link H, Mix E, Olsson T, Huang W-X. Th1-like cell responses to peripheral nerve myelin components over the course of experimental allergic neuritis in Lewis rats. Acta Neurol Scand 1994;90:19-25.
8. Zhu J, Link H, Weerth S, Linington C, Mix E, Qiao J. The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1. J Neurol Sci 1994b;125:132-7.
9. Zhu J, Mix E, Issazadeh S, Link H. Dynamics of mRNA expression of interferon-γ, interleukin 4 and transforming growth factor-β in sciatic nerves and lymphoid organs in experimental allergic neuritis. Eur J Neurol 1996;3:232-40.
10. Gutierrez-Rodriguez O, Starusta-Bacal P, Guierrz-Montes OJ. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989;16:158-63.
11. Guex-Crosier Y, Pittet N, Herbort CP. The effect of thalidomide and supidimide on endotoxin-induced uveitis in rats. Graefes Arch Clin Exp Ophthalmol 1995;233:90-3.
12. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 1991;84:103-8.
13. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
14. Cole CH, Rogers PC, Pritchard S, Phillips G, Chan KW. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant 1994;14:937-42.
15. Boughton BJ, Sheehan TM, Wood J, et al. High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Ann Clin Biochem 1995;32:79-83.
16. Uthoff K, Zehr KJ, Gaudin PB, et al. Thalidomide as replacement for steroids in immunosuppresion alter lung transplantation. Ann Thorac Surg 1995;59:277-82.
17. Schröder JM, Sellhaus B, Wöhrmann T, Kögel B, Zwingenberger K. Inhibitors effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early Wallerian degeneration. Acta Neuropathol 1995;89:415-9.
18. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984;11:814-9.
19. Keenan RJ, Eiras G, Burckart GJ, et al. Immunosuppressive properties of thalidomide: inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation 1991;52:908-10.
20. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
21. Tramontana JM, Utaipat U, Moilo A, et al. Thalidomide treatment reduces tumor necrosis factor α production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.
22. Neubert R, Nogueira AC, Noubert D. Thalidomide and the immune system 2. Changes in receptors on blood cells of a healthy volunteer. Life Sci 1992;51:2107-16.
23. McHugh SM, Rifkin IR, Deighton J, et al. The immunopathology drug thalidomide induced T helper production in mitogen- and antigen-stimulated human peripheral Mood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-2.
24. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
25. Norton WI, Poduslo SE. Myelination in rat nerve: method of myelin isolation. J Neurochem 1973;21:749-57.
26. Montani MS, Tuostol L, Delfini M, et al. A new tripeptide, POL509, influences biochemical events associated with antigen presentation efficiency of PPD-specific EBV-B cells. Immunopharmacology 1993;25:51-63.
27. Van der Meide PH, Dubbeld M, Vijverberg K, Kos T, Schellekens H. The purification of rat gamma interferon by use of two monoclonal antibodies. J Gen Virol 1986;67:1059-71.
28. Mix E, Olsson T, Solders G, Link H. Effect of ion channel blockers on immune response and course of experimental allergic neuritis. Brain 1989;112:1405-18.
29. Olsson T, Wang W-Z, Höjeberg B, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen induced secretion of interferon-gamma. J Clin Invest 1990;86:981-5.
30. Kaplow LS. Substitute for benzidine in myeloperoxidase stains. Am J Clin Pathol 1974;63:451.
31. Czerkinsky C, Nillsson Lå, Nygren H, Ouchterlony Ö, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody secreting cells. J Immunol Methods 1983;65:109-21.
32. Zhu J, Mix E, Olsson T, Link H. Cellular mRNA expression of interferon-γ, interleukin 4 and transforming growth factor-β by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis. Clin Exp Immunol 1994;98:306-12.
33. Hartung HP, Schäfer B, van der Meide PH, Fierz W, Heininger K, Toyka KV. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann Neurol 1990;27:247-57.
34. Schmidt B, Stoll G, van der Meide P, Jung S, Hartung HP. Transient cellular expression of gamma-interferon in myelin-induced and T-cell line-mediated experimental autoimmune neuritis. Brain 1992;115:-1633-46.
35. Zettl UK, Gold R, Toyka KV, Hartung HP. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol 1995;4:540-7.
36. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-701.
37. Nishimura K, Hashimoto Y, Iwasaki S. (S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomide effects. Chem Pharm Bull (Tokyo) 1994;42:1157-9.
38. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper 1- but not type 2-associated lymphokine production, presents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993;23:1745-51.
39. Vosgerau JC. Autoimmunity in human immunodeficiency virus infection and the use of thalidomide. Panminerva Med 1994;36:1-4.
40. Vilanova M, Ribiro A, Carneiro J, Arala-Chaves M. The effects of thalidomide treatment on autoimmuneprone NZB and MRL mice are consistent with stimulation ot the central immune system. Scand J Immunol 1994;40:543-8.
41. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-32.
42. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol 1994;30:66-9.